Abstract
Worsening of ventricular arrhythmias has been reported during therapy with class I antiarrhythmic agents. 1 N-acetyl procainamide (NAPA), the first metabolite of procainamide, has been implicated as a cause of polymorphic nonsustained ventricular tachycardia (VT) in 1 patient. 2 Sudden death has occurred during NAPA therapy, but recurrent ventricular fibrillation (VF) resulting from NAPA treatment alone has not been documented previously. 3,4 The following case demonstrates this phenomenon.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
